Bevacizumab-associated diverticulitis

Community Oncology

Volumn 5, Issue 1, 2008, Pages 31-32

  McKoy, June M ^a   Patel, Jyoti ^a   Courtney, D Mark ^a   Bolden, Carlos R ^a   Bennett, Charles L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; FLUOROURACIL; PACLITAXEL; PEMETREXED; VASCULOTROPIN;

ABDOMINAL PAIN; ANGIOGENESIS; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INTESTINE PERFORATION; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; PERITONITIS; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; VEIN THROMBOSIS; VOMITING;

EID: 38949110270     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1548-5315(11)70180-2     Document Type: Short Survey

References (2)

1. Patel JD, Hensing TA, Villafor V, Hart E, Bonomi P. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer. J Clin Oncol 2007;25(18S)7601.
2. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006;63:334-337.